secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2026-05-13T10:30:53+00:00
Accession:  0001816590-26-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission
--------------------------------------------------------------------------------

- FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.
- Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.
- Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).
- R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).
- Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/0001816590-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/cmps-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001816590-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer